Mohammad AskarPublic working copy · medical review pending

Inherited retinal disease · 115

Inherited retinal disease: phenotype, genetics and practical care

Combine the clinical pattern with retinal function and genetic evidence; look for treatable mimics and systemic disease.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

A genetic result and an imaging sign need clinical interpretation. Early rehabilitation and appropriate systemic assessment matter even when a disease-specific treatment is unavailable.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Start with the phenotype and the patient’s needs

Inherited retinal diseases (IRDs) are a heterogeneous group affecting photoreceptors, retinal pigment epithelium (RPE) or related tissues. They are an important cause of visual impairment in working life; historical blindness-registration findings from particular countries do not establish a universal current ranking across industrialised nations. 2 3 20

Record onset, progression, central or peripheral difficulties, colour vision, photophobia and night vision. Ask practical questions: finding a seat in a dark cinema or needing a torch earlier than companions while camping can reveal longstanding low-light difficulty. Night blindness suggests rod-system dysfunction, but does not by itself distinguish progressive retinitis pigmentosa (RP) from congenital stationary night blindness (CSNB). 2 3

Examine refraction, visual acuity, anterior segment, intraocular pressure (IOP), optic disc and dilated fundus before selecting further tests. Bilateral similarity can support the pattern, but is not proof of a genetic cause; asymmetry should prompt a careful differential assessment rather than an automatic rejection of inherited disease. Explore hearing, balance, neurological, cardiac and metabolic symptoms. Select visual-field testing for the clinical question and the person’s ability to perform it. 2 3

02Exclude acquired mimics and recognise a change in tempo

Take a current and past medication history. Hydroxychloroquine can cause parafoveal or pericentral toxicity; a bull’s-eye appearance is not required for early disease. Pentosan polysulfate maculopathy can resemble a pattern dystrophy, while didanosine exposure can be associated with peripheral chorioretinal atrophy. These acquired patterns can also be bilateral. 2 3 16 17 18

Distinguish lifelong symptoms from a newly acquired or rapidly changing disorder. Inflammatory, infectious, autoimmune/paraneoplastic and toxic disease can resemble IRD, and an inherited condition does not prevent a second diagnosis. Missing an exposure history is a clinical pitfall; there is no verified rule that it automatically causes failure in a specialist examination. 2 3 15

A stable history and a characteristic functional pattern can support a stationary disorder, but a single test does not prove lifelong stability. Achromatopsia often shows severely reduced cone responses with preserved or near-preserved rod function; slow structural change can still occur. Explain the likely course with its uncertainty and arrange disease-appropriate follow-up. 2 12

03Use the pedigree to ask the right genetic question

Build a pedigree across at least 3 generations when feasible, including apparently unaffected relatives, age at assessment and consanguinity. Standard symbols include a square for male, a circle for female and shading for affected status. A single affected family member does not establish recessive inheritance or exclude a genetic disorder. 2 3 21

In a usual heterozygous autosomal-dominant (AD) model, each pregnancy has a 50% chance of transmitting the variant; reduced penetrance and variable expression affect whether and how disease appears. Vertical transmission is a clue, not an obligatory pedigree shape. New variants and small or incompletely assessed families can obscure it. 21

For autosomal-recessive (AR) disease, the reproductive risk depends on both partners’ variants in the same relevant gene. The original general <1% estimate for children of an affected person with an unrelated partner is not a universal counselling figure; lack of known consanguinity does not establish that the partner is not a carrier. Affected status, carrier testing, gene and population context are needed. 21

A recessive condition can appear in successive generations when an affected person has children with a carrier; this is pseudodominance, discussed in the original ABCA4 example. Consanguinity and a relatively common disease allele can affect the likelihood, but do not replace a gene-specific family assessment. Refer for genetic counselling rather than assigning a generic population risk. 2 21

In ordinary X-linked inheritance there is no father-to-son transmission of the father’s X-linked variant. Females with a variant may nevertheless have retinal findings or clinically important disease; examine them rather than assuming they are unaffected carriers. Original examples include a tapetal-like radial golden reflex with RPGR, RPE mottling in ocular albinism, and mottling or peripheral atrophy in choroideremia; none is a stand-alone genotype test. 13 21

Maternal inheritance applies to pathogenic mitochondrial-DNA variants; a mitochondrial cellular mechanism can also arise from a nuclear gene with a different inheritance pattern. DNAJC30-associated autosomal-recessive Leber hereditary optic neuropathy (LHON) illustrates this distinction. Danon disease due to LAMP2 is X-linked and can seriously affect females as well as males. 11 21

04Interpret imaging as a clue rather than a gene result

Optical coherence tomography (OCT) evaluates the ellipsoid zone (EZ), outer nuclear layer, RPE and inner retina. Compare structural findings with symptoms and function, and look for macular oedema, schisis or another treatable complication. A normal global electroretinogram does not exclude a localised maculopathy. 2 3

Fundus autofluorescence (FAF) documents the spatial pattern of RPE-related signal; wide-field imaging helps when disease is peripheral. A hyperautofluorescent ring in RP may outline a transition in structure and function. Record acquisition settings and anatomy; neither an FAF ring nor peripapillary sparing is a unique molecular diagnosis. 2 3

The original teaching names “Robson-Ring” and “Nosbore-Ring” describe contrasting central/peripheral patterns, but the latter name and its exact provenance remain unresolved. Preserve the names in the terminology record and describe the observed pattern directly. Reversing a name is a mnemonic, not a validated diagnostic rule. 2 3

Very low short-wavelength FAF in early-onset severe retinal dysfunction can raise suspicion of RPE65-related visual-cycle disease. The original “Photographer Apology Sign” is a teaching label, not a substitute for checking image quality, retinal viability and molecular diagnosis. Prompt specialist assessment is useful, but an absent FAF image alone is not an acute emergency or proof of gene-therapy eligibility. 6 8

The original RPE65 FAF case series found absent or minimal signal in 10 affected patients, with 6 heterozygous parents and 2 other early-onset dystrophy comparators. This small selected series supports an imaging clue; it does not establish diagnostic specificity in every setting. Distinguish a low signal caused by biochemical change from established loss of retinal tissue. 8

Interpret imaging as a clue rather than a gene result
Imaging findingPossible gene / disorderClinical interpretation
Peripapillary sparing / flecksABCA4 / Stargardt diseaseA useful pattern to correlate with phenotype and genetics; not a unique diagnostic sign.
Very low short-wavelength FAFRPE65Consider early-onset visual-cycle disease; confirm genotype and viable retina before treatment assessment.
Tapetal-like radial reflexRPGRMay occur in an X-linked carrier phenotype; assess function and molecular evidence.
Cystoid spaces / schisisRS1 / CRB1OCT overlap requires functional and genetic differentiation; spaces are not automatically inflammatory oedema.
Original hyperreflective foci at the external limiting membrane (ELM)LAMP2 / Danon diseaseLayer attribution and original case source remain unverified; primary reports describe other outer-retinal findings too. Assess systemic clues.

05Read the ERG in its clinical context

The full-field electroretinogram (ffERG) measures retina-wide rod and cone pathway function under dark-adapted (DA) and light-adapted conditions. It contributes little direct information about a small central lesion; multifocal or pattern ERG may answer a different question when fixation permits. Use ISCEV methods and appropriate reference data. 2 4

An electronegative bright-flash ERG, including DA 10.0, has a disproportionately reduced b-wave relative to the a-wave; in the original teaching pattern, b < a. Measure a-wave amplitude from baseline and b-wave amplitude from the a-wave trough. With a relatively preserved a-wave, this suggests post-phototransduction dysfunction; a low b:a ratio with a severely reduced a-wave needs a broader interpretation. 4 15

CSNB and X-linked retinoschisis (XLRS) are familiar inherited differentials, but an electronegative waveform is not specific to them. Retinal ischaemia, toxicity and autoimmune/paraneoplastic disease can also produce it. Combine onset, examination, imaging, family history and additional electrophysiology rather than diagnosing from the trace alone. 4 15

New adult-onset night-vision symptoms with a CSNB-like ERG should raise the possibility of melanoma-associated retinopathy (MAR), including when the tumour is not yet known. This warrants prompt coordinated clinical investigation for acquired/paraneoplastic causes. The pattern alone neither proves melanoma nor mandates the same PET-CT pathway for every patient. 15

In a prospective molecularly confirmed achromatopsia cohort of 38 people, mean follow-up was 19.5 months; 2 of 37 serial OCT assessments changed, while reduced-FAF areas slowly enlarged in a subset. Small numbers and short follow-up limit lifetime prognosis. The finding supports slow or limited change in many patients, rather than a guarantee of permanent stationarity. 12

06Choose and interpret genetic testing with counselling

Single-gene analysis, multigene panels, exome sequencing and whole-genome sequencing (WGS) have different strengths and blind spots. Work with a qualified laboratory and genetic service, with appropriate information and consent. A negative or inconclusive result can merit reanalysis as methods and knowledge improve; it does not reliably exclude IRD. 2 3 5

A variant of uncertain significance (VUS) must not be treated as a confirmed molecular cause or used alone for a major treatment or reproductive decision. Assess variant classification, the required number and phase of alleles, phenotype and segregation. Avoid retrofitting the clinical diagnosis to an attractive but insufficiently supported laboratory result. 5

ABCA4 is a frequent cause in some genetically characterised retinal-disease cohorts and can produce Stargardt or cone-rod phenotypes. The original >20% figure requires its population and denominator; it is not a universal share of all IRD. Similar phenotypes can have other genetic or acquired causes. 2 3

“The fat red cat” illustrates reading-frame triplets. A 9-base coding deletion, as in the original CRB1 example, can preserve the frame, whereas deletion of 1 or 4 coding bases can shift it; location, transcript, splicing and biological context still matter. In-frame does not automatically mean mild, and frameshift does not always mean complete protein destruction or the most severe clinical course. 5 10

A well-supported diagnosis can redirect care and prevent inappropriate treatment, but genetic and inflammatory disease can coexist. The original examples of prolonged steroid or immunosuppressive treatment under an incorrect uveitis diagnosis remain teaching observations without a verified case series. Do not stop treatment solely because of a VUS; reassess the full clinical evidence. 2 3 5

07Connect the ocular phenotype with systemic care

Consider the original teaching vignette of a 16-year-old with cardiomyopathy and retinal hyperreflective foci. Danon disease should prompt coordinated cardiac and genetic assessment because LAMP2 disease can be life-threatening. The original ELM location and claim that the retinal diagnosis established a life-saving transplant indication are unverified; the cardiac team determines transplantation from the systemic assessment. 13 14

LAMP2 retinal findings vary, and some individuals show ocular signs with few other recognised features. Reports describe RPE and outer-retinal changes, including outer nuclear layer foci; do not make the original ELM label a diagnostic criterion. Males are often more severely affected, but female disease can also be significant. 13 14

The original LHON-mimic scenario illustrates optic neuropathy due to biallelic nuclear DNAJC30 variants. A primary series described 33 previously unsolved patients from 29 families with autosomal-recessive LHON, including incomplete penetrance. Distinguish this from mitochondrial-DNA LHON when counselling siblings and relatives; it is not simply another retinal dystrophy. 11 21

CRB1 maculopathy can resemble RS1-associated XLRS on OCT. Small primary reports document foveal schisis with normal ffERG despite macular dysfunction; this differs from the common electronegative XLRS pattern but is not an absolute exclusion test. Family history, peripheral findings, electrophysiology and biallelic genetic evidence resolve the differential together. 9 10

RP with hearing loss should raise a syndromic differential such as Usher syndrome, including USH2A-associated disease. Arrange audiological and other relevant assessment rather than assuming the ocular label explains every systemic symptom. Recognising a syndrome can change care even without an ocular disease-modifying treatment. 2 3

08Discuss treatment, rehabilitation and realistic expectations

Voretigene neparvovec (Luxturna) is indicated in the EU for adults and children with vision loss from confirmed biallelic RPE65-associated retinal dystrophy and sufficient viable retinal cells. Assessment is made in a specialist service; the product is delivered subretinally by an experienced retinal surgeon. A gene name, low FAF or severe visual loss alone does not establish eligibility. 6 7

The open-label phase 3 trial randomised 31 participants to treatment or control (21 versus 10); after one withdrawal in each group before intervention, the modified intention-to-treat population was 20 versus 9. At 1 year, mean bilateral multi-luminance mobility test (MLMT) improvement was 1.8 versus 0.2 light levels: difference 1.6 (95% CI 0.72–2.41), p=0.0013. This measures navigation under different illumination, not a universal visual-acuity recovery. 7

Independent outcome graders were masked, although participants and most study personnel were not. Small size, selected RPE65 disease, sponsor funding, control crossover after 1 year and a discrete primary outcome limit generalisation and long-term comparison. Surgical risks include retinal tears/detachment, infection, pressure rise and other retinal damage; current EMA information also reports chorioretinal atrophy, sometimes progressive. 6 7

Offer low-vision aids, filters when helpful, orientation/mobility training, educational or work adjustments and psychosocial support early. Assess treatable complications such as cataract, macular oedema or secondary neovascularisation in the relevant specialist pathway. Follow-up depends on phenotype, progression, function and treatment rather than a single interval for every IRD. 2 3

Assess and manage coexisting glaucoma according to damage, pressure, remaining function and the person’s goals. Do not justify an intervention solely by a promise of future optogenetic treatment or electronic implants. Those topics require their own current evidence, eligibility and regulatory assessment; the original mention does not establish availability or benefit. 2 3

Explain that unregulated intravitreal “stem-cell” interventions can cause severe ocular harm. A published case series reported major visual loss after such injections; this is a harm signal, not an incidence estimate for every cell product. Distinguish unproven commercial offers from properly regulated clinical research; a registry listing alone does not prove safety or efficacy. 19

09Review the pattern and plan the next step

Revisit the working diagnosis when the tempo, imaging, function and genetic result do not fit. Discuss uncertainty openly and give a practical plan for further testing, rehabilitation and relevant systemic care. The original resources “Stone Rounds” and “RetiNET” remain named learning leads with unresolved exact links or identity; no current recommendation or affiliation is inferred. 2 3 5

Review the pattern and plan the next step
PhenotypeInheritanceKey finding / imagingGene focusPractical implication / limit
Stargardt diseaseAR in ABCA4 diseaseFlecks; possible peripapillary sparingABCA4Correlate phenotype/genotype; original >20% share is cohort-dependent and unverified.
Early-onset severe dystrophy, including Leber congenital amaurosis (LCA), or RPAR in biallelic RPE65 diseaseVery low short-wavelength FAF; original Photographer Apology labelRPE65Confirm molecular cause and viable retina for Luxturna assessment.
Usher syndromeARRP plus hearing impairmentUSH2A and other genesAudiology / interdisciplinary care; no single sign proves the genotype.
X-linked RPXLOften severe RP; carrier tapetal-like reflex can occurRPGRGenetic counselling; study access must be checked for the actual patient and date.
CSNBXL / AR / other gene-specific patternsElectronegative ERG in relevant subtypes; myopia can occurCACNA1F and other genesDifferentiate from progressive/acquired disease; confirm the subtype before prognosis.
Danon diseaseX-linkedVariable outer-retinal findings; original ELM foci unresolvedLAMP2Prompt systemic/cardiac assessment; ocular sign alone does not determine transplantation.
LHON-like optic neuropathyAR in DNAJC30 diseaseOptic neuropathy; assess function and exclude alternativesDNAJC30Counselling differs from mitochondrial-DNA LHON; not everyone with biallelic variants manifests disease.
What are the main learning points?

A genetic result and an imaging sign need clinical interpretation. Early rehabilitation and appropriate systemic assessment matter even when a disease-specific treatment is unavailable.

When is assessment urgent?

A suddenly new loss of vision, flashes/floaters with a curtain, a painful red eye or new neurological symptoms need prompt or emergency assessment according to the presentation. New cardiac symptoms, fainting or breathlessness also require urgent medical assessment; do not assume every new symptom is part of a known inherited eye condition.

References and access status

  1. 1
    Immutable original export; own archived lecture; recording and attribution unverified

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    AAO — Clinical Assessment of Patients with Inherited Retinal Degenerations,2022

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Complete official extracted text, table/footnotes and references read; not every underlying primary paper or PDF image.

  3. 3
    DOG/BVA/RG — S1AWMF045-023,v2/August2026

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Official identity and web-extracted clinical/method/reference sections,printed1–12,read; no full COI-table/pixel inspection. Ordinary download returned anti-bot HTML. Extracted reference mismatch remains in the evidence ledger.

  4. 4
    ISCEV — full-field clinical ERG standard,2022; PMID35511377

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Selected primary physiology,clinical application and amplitude-definition sections read; not complete standard or figures.

  5. 5
    ACMG/AMP — sequence-variant interpretation consensus,2015

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Selected primary scope,classification,reanalysis and clinical-use sections read; not all later gene-specific refinements.

  6. 6
    EMA — previously inspected Luxturna product information

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Actual official English PDF extracted; 4.1 and selected 4.2,4.3–4.4 and the chorioretinal-atrophy part of 4.8 read. German 2.1 and 4.1 also read for the ingredient name and indication. Not the complete product information, Arabic label or a procedural protocol.

  7. 7
    Russell et al. — voretigene phase3RCT,2017; PMID28712537

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Complete primary summary and selected main eligibility,randomisation,masking,outcome,analysis,discussion/safety passages read. Protocol,supplement,figures and full long-term follow-up unread.

  8. 8
    Lorenz et al. — RPE65FAF case series,2004; PMID15288992

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Complete indexed primary abstract read; main report/figures unread. Small selected case series,not universal diagnostic specificity.

  9. 9
    Vincent et al. — CRB1foveal retinoschisis,2016; PMID27258436

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Complete indexed primary abstract read; three affected people,not every CRB1phenotype. Main/supplement unread.

  10. 10
    CRB1-associated maculopathy — clinical/molecular study,2018

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Selected indexed primary results read,including focal dysfunction with normal ffERG and in-frame allele; not complete main report or supplements.

  11. 11
    Stenton et al. — recessive DNAJC30LHON,2021; PMID33465056

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Complete indexed primary abstract read; selected nuclear-gene series with incomplete penetrance. Main report/supplement unread.

  12. 12
    Aboshiha et al. — prospective achromatopsia cohort,2014; PMID25103266

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Complete primary abstract and selected introduction/initial methods read; not complete results/tables/figures or all newer follow-up.

  13. 13
    GeneReviews — Danon disease,revision2024

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Expert reference summary and suggestive findings read; not complete chapter or verification of the original16-year-old transplant vignette.

  14. 14
    LAMP2pigmentary retinopathy primary report,2020; PMID32533651

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Selected indexed primary OCT findings read,including outer nuclear layer foci; complete abstract/main report and original ELM claim not verified.

  15. 15
    Jiang/Mahroo — negative ERG review,2021; PMID34127841

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Complete indexed review abstract and selected acquired/MAR passages read; narrative synthesis,not a trial or validated universal oncology-imaging algorithm.

  16. 16
    AAO — HCQ screening,2025revision/published2026

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Official first-page major recommendations read as indexed extract; not complete report or every underlying study.

  17. 17
    Pearce et al. — pentosan pigmentary maculopathy,2018; PMID29801663

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Identity and selected indexed primary design/result passages read; retrospective case series,not an individual incidence estimate. Complete report/current local label unread.

  18. 18
    Didanosine retinopathy follow-up,2021; PMID34255599

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Identity and selected indexed primary design/result passages read; no complete report,current local label or incidence estimate.

  19. 19
    Kuriyan et al. — harms after unproven intravitreal cells,2017; PMID28296617

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Identity and selected primary case passages read; not complete report. Case-series harm signal,not a pooled risk estimate or a verdict on regulated cell research.

  20. 20
    Heath Jeffery et al. — Australian blindness registrations,2021

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Selected indexed primary registry-design/results passages read; historical country-specific registration,not a current global ranking. Complete report unread.

  21. 21
    MedlinePlus Genetics — inheritance patterns

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Official educational inheritance table read; not a gene-specific reproductive-risk model or full genetic counselling. The separate AR explanation was also inspected.

Original lecture link